Marie-Hélène Louis

Towards a new standardized method for circulating miRNAs profiling in clinical studies: Interest of the exogenous normalization to improve miRNA signature accuracy

Nicolas Vigneron, Matthieu Meryet‐Figuière, Audrey Guttin et al. · Molecular Oncology · 2016 · 84 citations · Full text

Life Sciences, Molecular Biology, Molecular Medicine +17

PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced

Abdelghani Jebahi, Marie Villedieu, Cécile Pétigny-Lechartier et al. · Cancer Letters · 2014 · 55 citations · Full text

Medicine, Oncology, Pharmacology +17

Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells☆

Marie Villedieu, Marie-Hélène Louis, Soizic Dutoit et al. · Gynecologic Oncology · 2007 · 47 citations

Medicine, Cell Biology, Oncology +13

The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737

Cécile Pétigny-Lechartier, Charlène Duboc, Abdelghani Jebahi et al. · Molecular Cancer Therapeutics · 2016 · 46 citations

Medicine, Oncology, Pharmacology +17

First Evidence That Oligopyridines, α-Helix Foldamers, Inhibit Mcl-1 and Sensitize Ovarian Carcinoma Cells to Bcl-x_L-Targeting Strategies

Céline Gloaguen, Anne Sophie Voisin‐Chiret, Jana Sopková‐de Oliveira Santos et al. · Journal of Medicinal Chemistry · 2015 · 45 citations

Medicine, Oncology, Pharmacology +15